Catabasis is a private, venture-backed biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company’s lead compound for the treatment of type 2 diabetes is in clinical trials.